Cutler Group LP Akero Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	SELL	$17.76 - $31.18 $136,752 - $240,086	-7,700 Reduced 77.0%	2,300 $0
Q4 2023 Jan 18, 2024	SELL	$11.38 - $50.33 $6,828 - $30,198	-600 Reduced 5.66%	10,000 $0
Q2 2023 Jul 18, 2023	SELL	$36.89 - $56.88 $62,713 - $96,696	-1,700 Reduced 13.82%	10,600 $54,000
Q1 2023 May 01, 2023	SELL	$37.27 - $50.24 $264,617 - $356,704	-7,100 Reduced 36.6%	12,300 $59,000
Q4 2022 Feb 07, 2023	BUY	$33.44 - $54.8 $274,208 - $449,360	8,200 Added 73.21%	19,400 $297,000
Q3 2022 Oct 25, 2022	BUY	$10.15 - $34.05 $113,680 - $381,359	11,200 New	11,200 $61,000
Q4 2020 Jan 21, 2021	SELL	$25.12 - $29.89 $5,024 - $5,978	-200 Closed	0 $0
Q3 2020 Oct 27, 2020	BUY	$30.79 - $39.92 $6,158 - $7,984	200 New	200 $0

191

74.6M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.21B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.